Actively Recruiting

Phase Not Applicable
Age: 40Years +
MALE
NCT05879913

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

Led by Indiana University · Updated on 2026-02-25

100

Participants Needed

3

Research Sites

206 weeks

Total Duration

On this page

Sponsors

I

Indiana University

Lead Sponsor

N

National Comprehensive Cancer Network

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .

CONDITIONS

Official Title

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

Who Can Participate

Age: 40Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent and HIPAA authorization for release of personal health information
  • Age 40 years or older at time of consent
  • Previous diagnosis of prostate cancer and currently receiving or planning to start ADT for more than 12 months
  • Allowed if receiving ADT plus androgen pathway inhibitors such as abiraterone, enzalutamide, apalutamide, or darolutamide
  • At least one risk factor for atherosclerotic cardiovascular disease (hypertension, hyperlipidemia, diabetes, tobacco use)
  • No current cardiac symptoms
Not Eligible

You will not qualify if you...

  • Concurrent treatment with chemotherapy (docetaxel, cabazitaxel, mitoxantrone) at time of consent
  • Presence of implantable cardioverter-defibrillator (ICD) or pacemaker
  • History of coronary stents, obstructive coronary artery disease, myocardial infarction, coronary artery bypass grafting, or atrial fibrillation
  • Renal dysfunction with creatinine clearance less than 35 ml/min
  • Allergy to iodinated contrast
  • Contraindication to medications used to regulate heart rate for CCTA scan (only for those in CCTA group)
  • Taking sildenafil or tadalafil for vasodilation, pulmonary hypertension, or benign prostatic hyperplasia (BPH); taking these for erectile dysfunction is allowed

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

IU Health Joe and Shelly Schwarz Cancer Center

Carmel, Indiana, United States, 46032

Actively Recruiting

2

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Indianapolis, Indiana, United States, 46202

Actively Recruiting

3

Methodist Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

Loading map...

Research Team

E

Elizabeth Rowe

CONTACT

A

Abhishek Khemka, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT | DecenTrialz